ライフサイエンスコーパス: abdominal pain

1 che, dizziness, lightheadedness, and chronic abdominal pain).

2 al gastrointestinal disorder (not related to abdominal pain).

3 R 11.79 [4.30-37.98], p<0.0001 for recurrent abdominal pain).

4 ented to our emergency department with acute abdominal pain.

5 domen was performed to evaluate the cause of abdominal pain.

6 year-old postmenopausal woman presented with abdominal pain.

7 ith the most common presenting symptom being abdominal pain.

8 e most common side effects were vomiting and abdominal pain.

9 ity, which contributes to their diarrhea and abdominal pain.

10 man presented with steadily worsening lower abdominal pain.

11 .5 years earlier, presented with progressive abdominal pain.

12 2 with zoster sine herpete, and 5 of 5 with abdominal pain.

13 be developed to treat patients with chronic abdominal pain.

14 pinal G-CSF as a target for treating chronic abdominal pain.

15 ruction and presented with symptoms of vague abdominal pain.

16 nsidered in patients with melanoma and acute abdominal pain.

17 stency and mucosal histology, and alleviated abdominal pain.

18 ediated analgesic activity, thereby reducing abdominal pain.

19 All 37 patients presented with abdominal pain.

20 ission for inadequate control of generalized abdominal pain.

21 or the physician's in the screening of acute abdominal pain.

22 ble alternative for children with functional abdominal pain.

23 ntified changes in IBS-C symptoms, including abdominal pain.

24 refractory symptoms of nausea, vomiting, and abdominal pain.

25 eported abnormal brain responses to expected abdominal pain.

26 red in the differential diagnosis of chronic abdominal pain.

27 000 pediatric ED visits were made for acute abdominal pain.

28 blems with sexual dysfunction and 11.9% with abdominal pain.

29 d in evaluation of a teenage girl with lower abdominal pain.

30 most common presentation in the Px group was abdominal pain.

31 These processes might link stress with abdominal pain.

32 of KOR agonists for the treatment of chronic abdominal pain.

33 n who presented with a sudden - onset severe abdominal pain.

34 cument acute appendicitis or other causes of abdominal pain.

35 disease generally represented by right lower abdominal pain.

36 dely associated with symptoms of fatigue and abdominal pain.

37 experienced erythema, wheezing, nausea, and abdominal pain.

38 ry from asymptomatic abdominal mass to acute abdominal pain.

39 15-year-old patient complained of paroxysmal abdominal pains.

40 ent episodes of carpopedal spasms and crampy abdominal pains.

41 [1%], and 1 of 311 patients with functional abdominal pain [0.3%]).

42 mon serious adverse event in both groups was abdominal pain (11 [4%] in the imatinib group, 14 [4%] i

43 aminotransferase concentration (12; 4%), and abdominal pain (11; 3%).

44 ophosphataemia (19 [6%]), anaemia (17 [5%]), abdominal pain (13; 4%), and elevated lipase level (15;

45 During follow-up, 70 of 450 patients with abdominal pain (15%), 53 of 387 with chest pain and/or d

46 ]), depression (124 [17%] of 713 responses), abdominal pain (178 [22%]), and ocular disorders (142 [1

47 bdominal migraine = 37 (1.9%) and functional abdominal pain = 180 (9.7%)].

48 for celiac disease in children with chronic abdominal pain; 2) the characteristics of those children

49 [13%] of 156 patients in the placebo group), abdominal pain (20 [13%] vs 12 [8%]), diarrhoea (16 [10%

50 18 [5%]), anaemia (30 [9%] vs 34 [10%]), and abdominal pain (20 [6%] vs 11 [3%]).

51 roup), neutropenia (40 [9%] vs 26 [6%]), and abdominal pain (21 [5%] vs 22 [5%]).

52 ecisions changed in 116 of 457 patients with abdominal pain (25%), 72 of 387 with chest pain and/or d

53 subjects: bloating (33% vs 7.2%, P < .0001), abdominal pain (27.3% vs 4.8%, P < .0001), nausea (23% v

54 yroidism (39 [21%] vs seven [7%]), and upper abdominal pain (31 [16%] vs six [6%]); those more common

55 clinical adverse events were fatigue (55%), abdominal pain (34%), and nausea (19%).

56 Common findings were abdominal pain (37 patients [84%]) and a palpable abdomi

57 %) presented with symptoms, especially upper abdominal pain (46%).

58 health care contact after RYGB surgery were abdominal pain (489 [34.2%]), fatigue (488 [34.1%]), and

59 , constipation (7.4% and 8.6% vs. 2.5%), and abdominal pain (5.8% and 7.2% vs. 4.1%).

60 The percentage of responders for abdominal pain (50.6% vs 42.2%; P = .018) was significan

61 iagnosis changed in 235 of 460 patients with abdominal pain (51%), 163 of 387 with chest pain and/or

62 were chronic watery diarrhea (93%), chronic abdominal pain (70%), significant weight loss (92%), hyp

63 s were diarrhea (86%), bloating (77.5%), and abdominal pain (71.3%).

64 Adults were more likely to present with abdominal pain (71.8% vs 40.7%; P < .001) and children w

65 , predominant symptoms included fever (91%), abdominal pain (84%), and vomiting (49%).

66 complications [PEF 28 (25.2%), NV 4 (3.6%), abdominal pain 9 (8.1%), infection 7 (6.3 %), AHD 13 (11

67 NoV infection symptoms of vomiting (93.4%), abdominal pain (90.4%), nausea (60.0%), and diarrhea (10

68 ever and >/=1 other finding (eg, headache or abdominal pain); a probable case required fever and a po

69 RCP pancreatitis (PEP), defined by new upper-abdominal pain, a lipase level more than 3-fold the uppe

70 35.1%) had the classical paediatric triad of abdominal pain, a palpable abdominal mass and bloody sto

71 , use of pain modulators, moderate to severe abdominal pain, a severe gastroesophageal reflex, and mo

72 Abdominal pain after cholecystectomy is common and may b

73 In patients with abdominal pain after cholecystectomy undergoing ERCP wit

74 Risk of persisting need for insulin or abdominal pain after having had two versus one asparagin

75 ys be remembered in patients presenting with abdominal pain after stent insertion.

76 pancreatitis, which was defined as new upper abdominal pain, an elevation in pancreatic enzymes to at

77 Due to persistent abdominal pain, an upper endoscopy was performed.

78 relative risk, 7.44 [95% CI, 0.97-56.88] for abdominal pain and 8.36 [95% CI, 1.10-63.15] for diarrhe

79 ing appendicitis in patients presenting with abdominal pain and a clinical suspicion of appendicitis

80 n gastrointestinal disorder characterized by abdominal pain and altered bowel habits in the absence o

81 dy, recurrence also required the presence of abdominal pain and an increase in white blood cells.

82 The trial included adults with IBS-D, mean abdominal pain and bloating scores of 3 or more, and loo

83 We measured improvement in worst abdominal pain and composite pain score using the Pain F

84 We studied 11 patients with abdominal pain and diarrhea caused by early-onset protei

85 nism of the delta-opioid receptor can reduce abdominal pain and diarrhea in patients with irritable b

86 n postmenopausal women, with a few months of abdominal pain and distension.

87 should be considered in a patient with upper abdominal pain and elevated amylase in the context of an

88 Symptoms (stools type, nausea, vomiting, abdominal pain and flatulence) were assessed by a self-a

89 One day following discharge from hospital abdominal pain and frequent non-bloody diarrhea recurred

90 epartment with complaints of breathlessness, abdominal pain and hematuria for the last 6 months.

91 e or adjacent organs typically presenting as abdominal pain and hemodynamic instability.

92 who had a composite response of decrease in abdominal pain and improvement in stool consistency on t

93 8-year-old female patient with complaints of abdominal pain and jaundice.

94 In an oral food challenge test, she felt abdominal pain and nausea only after eating fruit, along

95 A year after seeing a physician for abdominal pain and obstipation and being told he couldn'

96 patient presented with complaints of severe abdominal pain and palpable pulsatile abdominal mass loc

97 One patient with abdominal pain and salivary VZV DNA had perforated gastr

98 ove other gastrointestinal symptoms, such as abdominal pain and satiety.

99 ders, based on a composite of improvement in abdominal pain and stool consistency.

100 al center of all pregnant patients seen with abdominal pain and suspected appendicitis who were follo

101 sulphate and placebo groups were: heartburn, abdominal pain and the presence of black stools (all p <

102 er of potential diagnoses in pediatric acute abdominal pain and thereby guide diagnostic imaging sele

103 plication observed was nonspecific transient abdominal pain and transient hypotension.

104 However, the patient began to experience abdominal pain and vomiting after ingestion of egg appro

105 ncy Department with complaints of epigastric abdominal pain and vomiting.

106 ith jejunal diverticulitis accompanying with abdominal pain and vomiting.

107 9 year old girl presented with a history of abdominal pain and vomiting.

108 symptoms of obstructive jaundice, including abdominal pain and yellowing of the skin.

109 toms, one case of back pain, and one case of abdominal pain) and one unexpected serious adverse event

110 onal dyspepsia, and 311 as having functional abdominal pain, and 210 children were excluded from the

111 verse events included hot flushes, alopecia, abdominal pain, and back pain.

112 nt with the classic symptoms of weight loss, abdominal pain, and bloody diarrhea, many present with n

113 than treatment-naive patients in the Reflux, Abdominal pain, and Constipation domains (4.3 [4.2-4.4]

114 I responders experienced more severe reflux, abdominal pain, and constipation than did treatment-naiv

115 with trichinellosis, characterized by fever, abdominal pain, and diarrhea, along with eosinophilia ra

116 ke, vascular diseases, cancer, trauma, acute abdominal pain, and diffuse lung diseases, as related to

117 Demographic characteristics, risk factors, abdominal pain, and disease burden.

118 ly considered related to RG1068 were nausea, abdominal pain, and flushing; most were mild.

119 ons in pancreatic enzymes, re-admissions for abdominal pain, and incidentalomas.

120 f gradually worsening headaches, vague upper abdominal pain, and lower back pain.

121 strointestinal side effects of constipation, abdominal pain, and nausea.

122 Adverse events included mild diarrhea, abdominal pain, and nausea.

123 Hemorrhage, abdominal pain, and perforation were the most common cau

124 rent fever, fatigue, elevated liver enzymes, abdominal pain, and significant weight loss.

125 luding colonic (ie, perforation, hemorrhage, abdominal pain), anesthesia-associated (ie, pneumonia, i

126 ely to have a headache, dizziness, myalgias, abdominal pain, anorexia, leukopenia, lymphopenia, throm

127 conditions in patients with IBD are chronic abdominal pain, anxiety, and depression.

128 (three [8%]) and anaemia, thrombocytopenia, abdominal pain, anxiety, and dyspnoea (two [5%] each).

129 nonoperatively treated right lower quadrant abdominal pain are less than 14% and may be safely and e

130 events, such as diarrhea, nausea, and upper abdominal pain, as well as decreased lymphocyte counts a

131 Abdominal pain assessed by the Numeric Rating Scale and

132 e paradoxical development of or increases in abdominal pain associated with continuous or increasing

133 contributes to visceral hypersensitivity and abdominal pain associated with many gastrointestinal dis

134 crete episodes of severe, unexplained crampy abdominal pain associated with nausea.

135 r cGMP is an important mechanism of reducing abdominal pain associated with this disorder.

136 ity during an initial evaluation for chronic abdominal pain at a pediatric tertiary care center.

137 HAE-FXII) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due

138 s characterized by relapsing skin swellings, abdominal pain attacks, and, less frequently, potentiall

139 block group were heartburn or dyspepsia and abdominal pain attributed to therapy; all were reported

140 after a single 250 mg dose (one subject) and abdominal pain, back pain, and eczema after multiple dos

141 Abdominal pain, bloating and weight loss were the common

142 Its symptoms include chronic abdominal pain, bloating gas, diarrhea and constipation.

143 ic emptying and vomiting, as well as nausea, abdominal pain, bloating, and early satiety compared wit

144 ylobacter infection [grade 3]; recurrence of abdominal pain, bloating, diarrhoea, and urinary tract i

145 Secondary end points included nausea, abdominal pain, bloating, early satiety, as well as the

146 the severity of 5 gastrointestinal symptoms (abdominal pain, bloating, nausea, gas, and fullness) bef

147 ion and pruritus on her neck, with flushing, abdominal pains, breathing difficulties, and syncope.

148 years) consecutively referred for recurrent abdominal pain by their primary care physicians without

149 oenterology outpatient department with acute abdominal pain centered in the epigastrium.

150 0%, and 13%, respectively, for patients with abdominal pain, chest pain and/or dyspnea, and headache;

151 ncy department who were referred for CT with abdominal pain, chest pain and/or dyspnea, or headache w

152 with overt GI bleeding, occult GI bleeding, abdominal pain, chronic diarrhea, and abnormal imaging r

153 scenario is a young patient presenting with abdominal pain, chronic diarrhoea, weight loss, and fati

154 s managed nonoperatively progress to chronic abdominal pain compared with 5% to 25% of patients treat

155 tients (70%) had at least a 30% reduction in abdominal pain compared with patients given placebo (50%

156 table bowel syndrome (IBS), a common chronic abdominal pain condition, we show evidence for sex and d

157 taking add-on antidepressants suffered from abdominal pain, constipation, dizziness, and dry mouth.

158 ENS or developmental defects cause vomiting, abdominal pain, constipation, growth failure, and early

159 Of 188 reported AEs, diarrhea, flatulence, abdominal pain/cramping, and constipation were most comm

160 ) have ongoing bowel symptoms of diarrhea or abdominal pain despite mucosal healing.

161 estinal disorder characterized by persistent abdominal pain despite recovery from acute gastroenterit

162 ally observed in patients with IBD including abdominal pain, diarrhea, and poor growth.

163 ulcerative colitis and Crohn's disease) are abdominal pain, diarrhea, and weight loss.

164 disease (EVD) symptoms (eg, fever, headache, abdominal pain, diarrhea, emesis, and fatigue) with symp

165 Presenting symptoms included abdominal pain, diarrhea, vomiting, food intolerance, an

166 ron salts (i.e. nausea, vomiting, heartburn, abdominal pain, diarrhoea, and constipation).

167 The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after al

168 n presented to his local hospital with acute abdominal pain, diarrhoea, and vomiting, and was admitte

169 iac disease testing in children with chronic abdominal pain did not occur, a large number of these ch

170 rs" (AP-FGID) has been changed to functional abdominal pain disorders (FAPD) and we have derived a ne

171 (heartburn, regurgitation), Indigestion, and Abdominal pain domains of the GSRS, both in partial PPI

172 to a hospital in Ethiopia because of severe abdominal pain during labor, with cessation of contracti

173 Therefore, patients present with cyclical abdominal pain during menstruation along with normal men

174 11, para 8) presented with increasing severe abdominal pain during the first trimester of pregnancy a

175 Average duration of abdominal pain episodes correlated with GE (r = -0.58, p

176 food causes bloating, overfilled intestines, abdominal pain, excessive feces, steatorrhea, and malnut

177 He reported abdominal pain, facial and jaw pain, anorexia, lethargy,

178 sented with a variety of symptoms, including abdominal pain, fatigue, muscle weakness, and low plasma

179 rrence of diarrhea, unexplained weight loss, abdominal pain, fever, and night sweating should alert p

180 ultiple episodes of melena, constipation and abdominal pain for one year duration is presented.

181 hy (five [28%]), diarrhoea (five [28%]), and abdominal pain (four [22%]).

182 Initially, he had abdominal pain, gastrointestinal bleeding and hypotensio

183 s, especially in patients who presented with abdominal pain, GI bleeding, or focal abnormalities on i

184 Scores obtained for severity of abdominal pain had a negative correlation with A (r = -0

185 on-specific physical symptoms (NSPS) such as abdominal pain, headache and musculoskeletal pain are wi

186 e CT scans, comorbid medical conditions (eg, abdominal pain, headaches), and measures of health care

187 tection of salivary VZV DNA in patients with abdominal pain helps to identify putative enteric zoster

188 y care providers (PCPs) for CT evaluation of abdominal pain, hematuria, or weight loss were identifie

189 In patients with abdominal pain, hematuria, or weight loss, leading diagn

190 tis was defined as the presence of new upper abdominal pain, hyperamylasemia/hyperlipasemia (at least

191 Bleeding per rectum was present in 82%, abdominal pain in 49%, constipation in 23% and diarrhea

192 se of typhoid fever was defined as fever and abdominal pain in a person with either vomiting, diarrhe

193 Patients present with abdominal pain in association with altered bowel functio

194 that the rate of CT use in the evaluation of abdominal pain in children increased every year between

195 estinal disorder with the primary symptom of abdominal pain in conjunction with bloating and bowel mo

196 and extinction learning related to expected abdominal pain in patients with IBS and controls, this s

197 t the mechanism by which linaclotide reduces abdominal pain in patients with IBS-C.

198 also found that linaclotide reduces chronic abdominal pain in patients with IBS-C.

199 ced visceral hypersensitivity, symptoms, and abdominal pain in patients with IBS.

200 DNF) has been reported to be associated with abdominal pain in patients with irritable bowel syndrome

201 inction of conditioned fear to the threat of abdominal pain in subjects with IBS and healthy individu

202 bowel syndrome is characterised by worsening abdominal pain in the context of escalating or continuou

203 He had experienced similar episodes of abdominal pain in the past that had been treated with su

204 a for Adverse Events, version 4.03) included abdominal pain (in 18% of patients), nausea (8%), ascite

205 ents), rash (in 34%), dry skin (in 32%), and abdominal pain (in 22%).

206 66%), dizziness (in 60%), diarrhea (in 51%), abdominal pain (in 40%), and vomiting (in 34%).

207 se events were nausea (in ten participants), abdominal pain (in six), and vomiting (in five).

208 is is exemplified in the assessment of acute abdominal pain, in which a physician's palpation determi

209 Less common causes of acute abdominal pain include ingested foreign bodies, infected

210 ation fever (PEF), nausea and vomiting (NV), abdominal pain, infection, acute hepatic decompensation

211 Right lower quadrant abdominal pain is a common cause of emergency department

212 Recurrent abdominal pain is a prevalent health issue in childhood.

213 F REVIEW: Evaluation of the child with acute abdominal pain is challenging because of the wide range

214 Differential diagnosis can be difficult as abdominal pain is common in pediatric C1-INH-HAE, but al

215 s occurred more frequently, and headache and abdominal pain less frequently, in patients receiving ve

216 n a 39-year-old black woman diagnosed due to abdominal pain, lymphadenopathy and fever.

217 se of 20 comparison patients with functional abdominal pain matched for age, gender, and study type.

218 ts have had an appendectomy due to recurrent abdominal pain (n = 5) or parental wish (n = 1) during t

219 n = 129 [77.7%]), fatigue (n = 116 [69.8%]), abdominal pain (n = 90 [54.2%]), headache (n = 87 [52.4%

220 n=2), anaemia (n=1), pneumothorax (n=1), and abdominal pain (n=1, unlikely related).

221 o radiology department with history of lower abdominal pain, nausea and vomiting since 2 days which w

222 ry of 30-lb (13.6 kg) weight loss, chest and abdominal pain, nausea, bilious emesis, cough, and short

223 and we have derived a new term, "functional abdominal pain -not otherwise specified", to describe ch

224 One dose-limiting toxicity event (grade 3 abdominal pain) occurred at the 300-mg dose.

225 wo serious adverse events (biliary colic and abdominal pain), occurring in the same participant, were

226 brain injury (odds ratio, 3.54; P < .0001), abdominal pain (odds ratio, 4.01; P < .0001), and headac

227 t repeat treatment, defined as a decrease in abdominal pain of >/=30% from baseline and a decrease in

228 mbocytopenia (seven [7%] vs three [6%]), and abdominal pain (one [1%] vs three [6%]).

229 vent: autoimmune disorder (two [13%]), lower abdominal pain (one [7%]), fatigue (one [7%]), and influ

230 tients still needed insulin or had recurrent abdominal pain or both.

231 was not recommended in patients with chronic abdominal pain or diarrhea, in whom there was no evidenc

232 based on Rome III criteria, with symptoms of abdominal pain or discomfort for at least 2 days/wk) and

233 to define the presence of true IBS was lower abdominal pain or discomfort in association with a chang

234 e to a growth or mass, 20% to injury, 20% to abdominal pain or distension, and 10% to a non-injury wo

235 rritable bowel syndrome (IBS) and functional abdominal pain or functional abdominal pain syndrome (FA

236 severe asparaginase-associated pancreatitis (abdominal pain or pancreatic enzymes at least three time

237 The presence of abdominal pain or vaginal bleeding during early pregnanc

238 e studies of 100 or more pregnant women with abdominal pain or vaginal bleeding that evaluated patien

239 ), hemorrhage (OR, 1.28; 95% CI, 1.27-1.30), abdominal pain (OR, 1.07; 95% CI, 1.05-1.08), complicati

240 having IBS, functional dyspepsia, functional abdominal pain, or abdominal migraine.

241 rticularly in patients with symptoms such as abdominal pain, oropharyngeal complaints, neck lumps, an

242 (P < .01), 6 of 11 patients with unexplained abdominal pain (P < .001), and 0 of 8 patients with unre

243 cally significant within-group reductions in abdominal pain (p < 0.01), loose stools (p < 0.01), bloa

244 ating (P < .04), and of depression levels on abdominal pain (P = .007), reflecting a general upward s

245 in total scores (-0.5 vs. -0.12, P<0.0001), abdominal pain (P<0.001), diarrhea (P<0.001), and reflux

246 docetaxel in reducing dysphagia (p=0.02) and abdominal pain (p=0.01).

247 atitis was defined by at least two criteria: abdominal pain, pancreatic enzymes at least three times

248 miting frequency and symptom scores (nausea, abdominal pain, postprandial fullness, and bloating) on

249 n presented to the emergency department with abdominal pain preceded by approximately one month of fr

250 Abdominal pain predominant functional gastrointestinal d

251 observed between HRQoL score and severity of abdominal pain (r = -0.24, p < 0.0001).

252 resented with an acute onset of severe upper abdominal pain radiating to the back and vomiting.

253 The presence of abdominal pain reduced the risk (OR 0.5 (0.3-0.7)), whil

254 a case of an eight year old child with acute abdominal pain referred for USG and CT scan which reveal

255 children with a primary complaint of chronic abdominal pain referred to a tertiary care children's ho

256 Rome III "abdominal pain related functional gastrointestinal disor

257 ed the efficacy of PENFS in adolescents with abdominal pain-related functional gastrointestinal disor

258 d 11-18 years) who met Rome III criteria for abdominal pain-related functional gastrointestinal disor

259 alence of celiac disease in each category of abdominal pain-related functional gastrointestinal disor

260 Rome III classification of abdominal pain-related functional gastrointestinal disor

261 safe and effective therapies for paediatric abdominal pain-related functional gastrointestinal disor

262 8, 2015, and Nov 17, 2016, 115 children with abdominal pain-related functional gastrointestinal disor

263 S with Neuro-Stim has sustained efficacy for abdominal pain-related functional gastrointestinal disor

264 eduction from baseline of the weekly average abdominal pain score for 6 or more of 12 weeks of treatm

265 e 46% vs placebo 13%; P = .024), and reduced abdominal pain scores (ebastine 39 +/- 23 vs placebo 62

266 The primary efficacy endpoint was change in abdominal pain scores.

267 new associations was the prediction that the abdominal pain side effect of the synthetic oestrogen ch

268 M is a rare anomaly that presents with upper abdominal pain, signs of acute pancreatitis and massive

269 rl who presented with dysmenorrhea and lower abdominal pain since a few months.

270 tract infections (18 [17%] vs ten [9%]), and abdominal pain (six [6%] vs three [3%]).

271 ome, IBS, bloating, constipation, functional abdominal pain, sphincter of Oddi dyskinesia, pelvic flo

272 symptoms and higher frequencies of vomiting, abdominal pain, swollen stomach, and loss of appetite, c

273 Abdominal pain, symptom relief, and health-related quali

274 Centrally Mediated Abdominal Pain Syndrome (CAPS), formerly known as Functi

275 and functional abdominal pain or functional abdominal pain syndrome (FAP[S]).

276 yndrome (CAPS), formerly known as Functional Abdominal Pain Syndrome, can be distinguished from other

277 ; chest pain/dyspnoea; vaginal bleeding with abdominal pain; systolic blood pressure; and dipstick pr

278 old male was admitted due to recurring upper abdominal pain that lasted several weeks.

279 e individuals within a population defined by abdominal pain that might have enteric zoster.

280 cy department with subacute poorly localized abdominal pain that was increasing in intensity.

281 ib group were anaemia (seven [4%] patients), abdominal pain (three [2%] patients), and intestinal obs

282 Symptoms may range from mild abdominal pain to life-threatening obstruction and stran

283 of chronic constipation presents with severe abdominal pain to the emergency department.

284 ions were cancer and trauma for chest CT and abdominal pain, trauma, and cancer for abdominopelvic CT

285 ediate allergic reaction including erythema, abdominal pain, vomiting, and anaphylactic shock.

286 ins unknown, developed abruptly with fevers, abdominal pain, vomiting, diarrhea, dehydration, and hem

287 s as persons with gastrointestinal symptoms (abdominal pain, vomiting, diarrhea, or nausea) and neuro

288 temporomandibular disorder was 7% (1-31) and abdominal pain was 6% (1-28).

289 Pancreatitis-related abdominal pain was a major symptom in 81% of children wi

290 istory of hysterectomy presenting with vague abdominal pain was completely evaluated with ultrasound

291 Abdominal pain was the most common GI symptom that promp

292 ent for severe weakness, left lower quadrant abdominal pain, weight loss and diarrhoea.

293 ed with progressive illness characterized by abdominal pain, weight loss, anorexia, generalized weakn

294 ing frequency/NGT secretion volumes, nausea, abdominal pain, well-being, and safety were also assesse

295 sting need for insulin therapy and recurrent abdominal pain were associated with having had pseudocys

296 Diarrhea and abdominal pain were reported in 46% and 17% of patients

297 mild GI side-effects (dyspepsia, nausea and abdominal pain) were described in 4/22 subjects on activ

298 One hundred seventeen patients with acute abdominal pain who underwent abdominal CT were enrolled

299 an diosmectite and S. bouliardii in reducing abdominal pain, with a constant improvement observed thr

300 syndrome generally present with nonspecific abdominal pain, with the left renal vein (LRV) lodged be